Somewhat Positive News Coverage Somewhat Unlikely to Affect Theravance Biopharma (TBPH) Share Price

News stories about Theravance Biopharma (NASDAQ:TBPH) have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Theravance Biopharma earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1938906290379 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

TBPH has been the subject of a number of recent research reports. ValuEngine raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday. Cantor Fitzgerald initiated coverage on shares of Theravance Biopharma in a research note on Friday, June 16th. They set an “overweight” rating and a $55.00 price objective for the company. Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. BidaskClub cut shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Theravance Biopharma presently has a consensus rating of “Hold” and an average target price of $41.63.

Shares of Theravance Biopharma (NASDAQ:TBPH) traded down 0.28% during trading on Friday, hitting $31.77. 431,635 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $29.58 and its 200 day moving average is $35.23. Theravance Biopharma has a 1-year low of $23.15 and a 1-year high of $43.44. The firm’s market capitalization is $1.71 billion.

In other Theravance Biopharma news, CEO Rick E. Winningham purchased 10,000 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were bought at an average price of $24.50 per share, for a total transaction of $245,000.00. Following the purchase, the chief executive officer now directly owns 866,377 shares in the company, valued at approximately $21,226,236.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Frank Pasqualone purchased 4,000 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were acquired at an average price of $26.34 per share, for a total transaction of $105,360.00. Following the purchase, the senior vice president now owns 213,180 shares in the company, valued at $5,615,161.20. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 20,000 shares of company stock worth $494,300. Company insiders own 6.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Theravance Biopharma (TBPH) Share Price” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.truebluetribune.com/2017/09/17/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-theravance-biopharma-tbph-share-price.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Insider Buying and Selling by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply